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1. Introduction 
Basal Cell Carcinoma (BCC) is the most common  malignant tumour of the skin. It is also the 
most common cancer in humans in some countries. BCC is malignant neoplasm derived 
from nonkeratinizing cells originating in the basal layer of the epidermis. The histology of 
the tumour and the surrounding stroma is characteristic. 
Basal cell carcinoma was first described in 1824 by Jacob who called it "ulcus rodens"; its current 
nomenclature was proposed by Krompecher in 1903. It is the most common type of 
nonmelanoma skin cancer (80% of all skin cancers) and most common malignancy in humans. 
It is delivered from the basal layer of the epidermis or pluripotent bazaloid cells of adnex and 
almost seen in the areas of sun exposure and hairy parts of the skin. There are many factors in 
its etiology including genetic predisposition, immune deficiency and chronic sun exposure 
(Adisen & Gurer, 2007). Recently published studies major on genetic and molecular aspects of 
the pathogenesis of basal cell carcinoma. Metastasis is rare in BCC and local destruction and 
disfigurement are much more common (Sikar et al., 2011). BCC usually appears as a flat, firm, 
pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may 
bleed following minor injury. Tumor size can vary in diameter. Treatment options include 
electrodesiccation and curettage, surgical excision, cryosurgery, 5-fluorouracil, 5% imiquimod 
cream, and superficial radiographic therapy. Electrodesiccation and curettage are the most 
common treatments. Cure rate in these options is approximately 95%. 
Nevoid basal cell carcinoma syndrome or Gorlin-Goltz syndrome is an autosomal dominant 
disorder characterized by multiple basal cell carcinoma, multiple keratocystic tumors, and 
skeletal anomalies (Bader, 2011). 
2. Epidemiology 
Frequency of BCC has been increasing in many countries around the world. The American 
Cancer Society reports that it is the most common cancer in the United States. Approximately 
1 million new cases diagnosed in a year and more than 10,000 deaths occur (2% of all cancer 
deaths). The observed increase in incidence rates may be because of increased detection and 
skin cancer awareness in health policy. Increased longevity may also affect the increased 
incidence of BCC; recent data also suggest that incidence is also increasing in the young 
population. 
Because of its high frequency, the disease has been accepted to be a public health issue. 
Despite low mortality rates and the rare occurrence of metastases, the tumor may be locally 
invasive and relapse after treatment, causing significant morbidity. In BCC knowledge of 
risk factors, early diagnosis and treatment is the major point.  
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BCC incidence varies all around the world. In states near the equator, such as Hawaii, BCC 
incidence is approaching 3-fold more often than that of states in the Midwest, such as 
Minnesota (Bader, 2011). The highest rates of skin cancer occur in South Africa and Australia. 
In these areas exposure to UV radiation is in high dose. 
Ramani and Bennett reported a significantly  higher incidence of BCC in World War 2 
servicemen stationed in the Pacific theater than in those stationed in Europe (Carucci & 
Leffell, 2008). 
BCC is seen in all skin types, but dark-skinned individuals are rarely affected, and more 
common in fair-skinned individuals (type 1 or type 2 skin types ). People who have 
Fitzpatrick type 1 skin are very fair and have red or blond hair and freckles; these individuals 
always burn and never tan. People who have type 2 skin are fair and burn easily and tan 
minimally. 
Incidence is low in blacks, Asians, and Hispanics (Machado et al., 1996).  Also it was found 
that approximately 13 million white non-Hispanics living in the USA in early 2007 had at 
least one non-melanoma skin cancer. 
Among to gender men are affected twice as women. The higher incidence in men might be 
because of occupational exposure to the sun.  
BCC frequency increases with age. Except of basal cell nevus syndrome, BCC is rarely found 
in patients younger than 40 years. Approximately 5-15% of cases of BCC occur in patients 
aged  between 20 and 40 years. Aggressive-growth of basal cell carcinoma (AG-BCC) is 
more frequently noted in patients younger than 35 years than in older individuals. 
Aggressive-growth of basal cell carcinoma includes morpheaform, infiltrating, and recurrent 
BCCs (Bader, 2011). 
3. Etiology and pathogenesis 
Its etiology is still unclear, but both constitutional and environmental factors and genetic 
predispotion are accused in BCC etiopathogenesis. The most important risk factor for basal 
cell carcinoma is exposure to UV-radiation (Bauer et al., 2011). Almost all basal cell 
carcinomas occur on parts of the body excessively exposed to the sun especially the face, 
ears, neck, scalp, shoulders, and back. Outdoor workers with a long history of work-related 
UV-exposure are at increased risk of developing BCC. Other risk factors include light skin 
phototypes, advanced age, family history of skin carcinoma, light-coloured eyes and blond 
hair, freckles in childhood and immunosuppression. Behavioral aspects such as 
occupational sun exposure, rural labor and sunburns at a young age also play a role (Bader, 
2011). CYLD is a deubiquitination enzyme that regulates different cellular processes, such as 
cell proliferation and cell survival. Mutation and loss of heterozygosity of the CYLD gene 
causes development of cylindromatosis, a benign tumour originating from the skin. Kuphal 
et al. suggested that suppression of CYLD has a significant role in basal cell carcinoma 
progression (Kuphal et al., 2011). 
Between 30% and 75% of the sporadic cases are associated with patched hedgehog gene 
(PTCH) which is a tumor suppressor gene located in the 9q22 (PTCH1) and 1p32 (PTCH2) 
location. This gene is almost with all cases associated with basal cell nevus syndrome. Other 
genetic changes are also described like experiments with activation of the hedgehog 
signaling pathway in different compartments of the epidermis and on the expression of 
cytokeratins 5, 14, 15, 17 and 19 with a follicular pattern, which has defined it as a malignant 
neoplasm of follicular germinative cells (trichoblasts) (Chinem, 2011; Youssef, et al., 2010). 
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Furthermore, there is an association of BCC with abnormalities of the sonic hedgehog gene 
(Donovan, 2009).  This hypothesis is further strengthened by the rarity of palmoplantar and 
mucosal lesions, where no hair follicles are found (Betti, 2005; Orsini 2001). Baskurt et al. 
have reported two brothers who have albinism and synchronous developed BCC on their 
trunk region. That means development of the same malignancy in the same life period at the 
similar localizations reminds the importance of genetic predisposition (Baskurt, 2011). 
BCC can rarely develop on unexposed areas. In some case reports, BCC of the prostate has 
been reported. Contact with arsenic, tar, coal, paraffin, certain types of industrial oil, and 
radiation are some factors playing role in BCC etiology (Kwasniak & Zuazaga 2011). 
BCC can also be associated with scars (eg, burn complications), xeroderma pigmentosum, 
previous trauma, vaccinations, or even tattoos (Bader, 2011). 
Lee et al. published a case report about expression of RUNX3 (Runt-related transcription 
factor 3) in skin cancers. They found that higher expression of RUNX3 is seen in several 
cancers, including basal cell carcinoma.  Expression of RUNX3 is reduced in a large number 
of cancers. As a result they suggest that RUNX3 has an oncogenic potential and does not act 
as a tumour suppressor in skin cancers (Lee et al., 2011).  
Activation of Gli-1 factor, induces the transcription of several oncogenes involved in the 
development of BCC and other malignancies. An other gene in BCC etiology is SMO gene 
which is a protein located in the membrane - smoothened -expressed by the SMO gene. 
Chinem et al. reported that mutations in the SMO gene are present in 10-21% of sporadic 
BCCs and mutations in the p53 gene are present in more than 50% of cases, although the p53 
gene is more related to the progression than the origin of BCC (Chinem & Miot, 2011).  
Fernandez –Flores reported a case about D2-40 immunoexpression in BCC etiology. They 
suggested that this immunoexpression was a prognostic connotation in carcinomas of 
organs other than the skin. In their case rapid grown had been seen over the last few months 
(Fernandez –Flores, 2011). 
Involvement of the trunk and development of multiple BCCs were related to genetic 
polymorphisms in glutathione S-transferase, NADPH and cytochrome P-450. Also trisomy 
of chromosome 6 was linked to increased aggressiveness of BCC (Chinem & Miot, 2011).  
Kwasniak et al. reported that BCC is one of the cancers most strongly associated with the 
atomic bombing in Japan. It is reported that residents of Nagasaki who were not exposed to 
atomic bomb radiation, the incidence of BCC was 3.1 per 100,000 while the survivors 
incidence was 9.4 per 100,000 people per year (Kwasniak & Zuazaga 2011). 
Tang et al. reported in their study that topical vitamin D3 treatment of existing murine BCC 
tumors significantly decreases Gli-1 and Ki-67 staining. Thus, vitamin D3 acting via its 
Hedgehog inhibiting effect may hold promise as an effective anti-BCC agent (Tang et al., 
2011). 
4. Clinical manifestations 
Basal cell carcinoma patients often present with a slowly growing, nonhealing sore of 
varying duration. The lesions are typically seen on the face (Figure 1), ears (Figure 2), scalp, 
neck, or upper trunk. Mild trauma initially may cause bleeding. A history of chronic sun 
exposure is commonly elicited. The early tumours are commonly small, translucent or 
pearly, raised and rounded areas located on a few dilated, superficial vessels. There are six 
subtypes of BCC that include nodular, superficial, pigmented, morpheaform, cystic and 
fibroepithelioma of Pinkus.  
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Fig. 1. Basal cell carcinoma as nonhealing sore on face. 
 
 
Fig. 2. Superficial spreading basal cell carcinoma located on ears. 
4.1 Nodular Basal Cell Carcinoma 
Nodular BCC is the most common subtype, accounting for more than 60% of all tumors. 
Lesions are clinically found on the head and neck regions. BCC can also be seen in sun-
protected areas. The nodular form of BCC appears as red or pink papules with raised, rolled 
borders that slowly enlarge (Figure 3 & 4). Red papules have a pearly or waxy appearance 
and telengiectasias are seen. On the microscopic examination; BCC is composed of well-
defined, smooth-bordered basophilic staining islands of neoplastic cells. Melanin 
pigmentation of tumor cells and adjacent stromal histiocytes may be seen. Mitoses and 
individual cell necrosis are uncommon. The surrounding stroma showing myxoid change, is 
rarely fibrotic and may show calcification in discrete islands of tumour or in adjacent 
stroma. This subtype of BCC grows slowly; however if left untreated for enough time, it can 
invade structures and increase morbidity (Miller, 2008; Nouri, 2007 & Schwartz, 2008). 
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Fig. 3. Rodent ulcer type of basal cell carcinoma 
 
 
Fig. 4. Nodular type of basal cell carcinoma. 
According to some authors multinodular BCC is accepted as an another subtype of BCC. It 
manifests a plaque-like indurated lesion with poorly demarcated contour. Lesions may be 
difficult to remove and so have an increased incidence of recurrence. In the pool data, 
subjects with a micronodular BCC had a mean age comparable with subjects with a 
superficial BCC but were younger than subjects with nodular or an infiltrative BCC (Betti et 
al., 2010). 
In one study, it was found that nodular BCC is associated with increased hyluronan 
homeostasis, when compared with normal skin. Also chondroitin sulphate were 
significantly higher, whereas dermatan sulphate was significantly lower in BCC when 
compared with normal skin. There may be a relationship between the proliferative activity 
of tumour cells and the stromal occurrence of hyaluronan and that this proliferative activity 
differed in the various types of BCC (Tzellos et al., 2010). 
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4.2 Pigmented Basal Cell Carcinoma  
This form of BCC consists of a brown, black, or gray blue color that can present on the head, 
neck, trunk or extremities. It appears as a hyperpigmented, translucent papule, which may 
also be eroded (Figure 5). These are usually extremely slow in evolving. This type is seen 
more frequently in dark-complexioned people such as Latin Americans or Japanese. 
Pigmented type constitutes approximately 6% of all BCC. Pigmented nevi, melanoma, 
pigmented Bowen’s disease are the most frequent clinical differential diagnosis for such 
lesions. Pigmented BCC shows similar histologic features with nodular type but there are 
large amounts of melanin. In dermoscopy; maple leaf like areas, spoke-wheel areas, large, 
blue-gray ovoid nests, multipl blue-gray globules, arborizing (tree-like ) telangiectasia and 
ulceration may be seen (Carucci, 2008; Odom, 2000 & Menzies 2002). 
 
 
Fig. 5. Hyperpigmented nodular basal cell carcinoma 
4.3 Superficial Basal Cell Carcinoma  
This subtype is the second common one and seen mostly on the trunk and extremities. 
Lesions are clinically flat, red to pink, scaly patches with ulcerations and crusting. The 
borders can be elevated or rolled. This thin threadlike border facilitates distinction from a 
plaque of Bowen’s disease or of psoriasis. It also presents at younger age than nodular type 
(average age is 57.5 vs 65.5 years). Superficial BCC  usually do not extend into the deep 
dermis, and a nonspecific inflammatory infiltrate may be seen in the papillary dermis. They 
usually grow laterally, and can reach unstantial sizes. Horizontal growth allows these 
tumours to extend significantly beyond the clinical borders (Figure 6).. 
Superficial BCC is characterized microscopically by buds of malignant cells extending into 
the dermis from the basal layer of the epidermis. The peripheral cell layer shows palisading. 
Tumour cells may colonize the hair follicle and rarely the ecrine adnexal structures.  Mitoses 
are infrequent, and apoptotic cells are rare in the atypical basaloid buds. When seen in the 
setting of a biopsy for suspect superficial BCC, a band-like lymphoid infiltrate should 
prompt a careful search through multipl levels looking for foci of superficial BCC (Nouri, 
2007; Schwartz, 2008 & Tzellos 2010). 
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Fig. 6. Slightly elevated borders of superficial type of basal cell carcinoma. 
In dermoscopy; according to a study, shiny white to red areas were seen in 100% of the 
lesions, while approximately 86% revealed short fine telangiectasias; they also described 
small surface ulcerations or erosions in about 78% of the lesions. Other dermoscopic criteria, 
such as leaf-like areas, arborizing telangiectasias, blue-gray globules, and large blue-gray 
ovoid nests, are not strongly associated with the diagnosis of superficial BCC (Scalvenzi et 
al., 2008). 
4.4 Morpheaform Basal Cell Carcinoma 
This type of BCC demonstrates waxy white sclerotic plaques occuring in the head and neck 
region, with a conspicious absence of a rolled edge. The exact margin of the lesion is 
impossible to define, but palpation reveals a firm skin texture that extends irregularly 
beyond the visible changes. Ulceration and crusting are also absent, whereas telangiectasia 
is prominent. The surface is smooth and may be slightly depressed below the normal level. 
The colour is yellowish, pink or white and may appear as a smooth shiny scar. These lesions 
are reported to be more frequent on the face in women and may be associated with 
smoking. The morpheaform BCC tends to develop at a younger age compared with other 
types, sometimes during adolescence. These lesions are usually misdiagnosed, leading to 
greater tumour growth and delayed treatment.  This is an aggressive growth variant of BCC 
(Mackie, 2004; Nouri, 2007; Schwartz, 2008 & Tzellos 2010). 
In histopathology; there is a fibrotic dermis that contains small, linear, and branching 
collections of basal cells. Morpheaform BCC islands typically are not well circumscribed and 
do not demonstrate prominent peripheral palisading of nuclei. Individual cell necrosis and 
mitotic activity are brisk considering the relative tumor volume and the neoplasms 
themselves are poorly demarcated, showing widespread invasion of the reticular dermis 
and penetration into the subcutaneus tissue (Nouri, 2007 & Tzellos 2010). 
4.5 Cystic Basal Cell Carcinoma 
This type of BCC is uncommon. It is usually seen around the eyes. This tumour shows 
differentiation towards the hair follicle infundibulum. A sebaceous component is usually 
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absent. It may appear as a blue-gray cystic nodule suggestive of an apocrine hidrocystoma. 
It has two subtypes. One is small cyst of light blue-gray coloration; other one is variable in 
size and may be quite large. Both subtypes are interfere with benign cutaneous cysts. It can 
not be clinically separated from hidrocystoma, as it too has a broad base, fine telangiectasias 
and a blue tint. Any cyst or inflammatory lesion of the eyelid which does not resolve within 
a reasonable period should be examined histologically (Braun-Falco, 2000; Nouri, 2007 & 
Tzellos 2010). 
4.6 Fibroepithelioma of Pinkus 
This type of BCC was first described by Pinkus in 1953. This is an uncommon variant of 
BCC. Fibroepitheliomas are usually soft pink or flesh-colored nodules or plaques on the 
trunk, especially the lumbosacral region. They are extremely rare on sunlight-exposed sites 
and do not ulcerate but erosions may be seen. They may be broad-based flat plaques or 
pedunculated, tending to be smooth surfaced with a pink or reddish colorationn, and 
characteristically appear on the lower back. They may be pigmented. They may follow 
many years after local X-ray therapy. 
Histopathologic findings include lacy strands of basaloid cells extending into a fibrous 
stroma. Some authors regard the fibroepithelioma as a form of fenestrated trichoblastoma, a 
lesion held to be a benign analogue of BCC that shares many morphological features of BCC 
but has not to date been shown to manifest PTCH mutations and dominantly affects sun-
protected skin (Braun-Falco, 2000; Nouri, 2007 & Repertinger, 2008). 
There are other rare clinical types of BCC. These are wild-fire BCC, giant-pore BCC, 
angiomatous BCC, lipoma-like BCC, and metatypical BCC. In wild-fire type; plaques  
expands rapidly with crusting, ulceration, and scarring. The giant pore BCC appears on the 
face as a 2-10 mm orifice, usually skin colored. It could represent a localized follicular 
abnormality. The angiomatous BCC is bluish or violaceous nodule with a somewhat cystic 
quality and is exceedingly rare. The lipoma-like BCC displays a remarkable clinical 
resemblance to the lipoma. Metatypical BCC is very rare and may simply be a subset of BCC 
that is radiation-resistant. They tend to be large aggressive tumors that usually have been 
unsuccessfully irradiated. They are seen on the back and nose (Braun-Falco, 2000; Hakverdi, 
2011 & Ting, 2005). 
5. Biological behavior 
5.1 Local Invasion 
Local invasion is the most important problem of BCC (Carucci, 2008 & Schwartz, 2008). It 
grows in a “silent” way into immediately adjacent tissue (Figure 7). It rarely metastasizes. 
The doubling time is between 6 months and 1 year. There may be irregular intrusions into 
certain tissues: dermis, fascial planes, periosteum, perichondrium, embryonic fusion 
planes and nerve sheath (Carucci, 2008). Tumor progression is slow in anatomic fusion 
planes. BCC located in embryonic fusion planes, periauricular region, tends to be at high 
risk of deep extension. It has been shown that the highest risk tumors which exhibit 
extensive subclinical spread are basosquamous and morpheaform BCC found on nose and 
morpheaform BCC on cheek and those with a preoperative size greater than 25 mm 
(Batra, 2002 & Schwartz, 2008). The tendency of BCC to spread into the dermis is 
understandable, because it develops immediately beneath the epidermis. Intradermal 
invasion may be clinically inapparent and moreover may prove quite asymmetrical, being 
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several times larger on side of BCC than on the other. Inapparent extensions often result 
in tumor recurrence after removal (Schwartz, 2008). 
 
 
Fig. 7. Advanced and invazive basal cell carcinoma of the right periorbital region.  
When BCC penetrates the dermis, additional expansion patterns may ocur (Schwartz, 2008). 
The biological behavior of the micronodular, infiltrating and sclerosing (morpheaform) 
variants of  BCC are known to be more aggressive than that of the nodular and superficial 
forms. These three “agressive growth” subtypes are characterized by an infiltrative growth 
pattern that has poor circumscription (Miller, 2008). 
BCC may spread along perichondrium of the nose or ear as the cutaneous and subcutaneous 
tissues are so thin there. The cartilage of the nose is quite irregular, small pockets of tumor 
spread in auricular and periauricular region appear to correspond to embryonic fusion 
planes (Schwartz, 2008). 
Stromal reaction tends to be sclerotic rather than fibroblastic or myxoid. The attraction of 
BCC for connective tissue is well recognized but not well understood. This stromal 
dependency is one of the basic characteristics of BCC (Miller, 2008). 
5.2 Perineural invasion 
The reported rate of perineural spread in all BCC is between 0.18% and 3%, and is present 
more often in deep specimens (Walling et al., 2004). Perineural invasion is more common in 
the aggressive subtypes of  BCC (micronodular, infiltrating and sclerosing variants) (Brown 
& Perry, 2000). 
What is the true incidence of perineural invasion among skin carcinomas? Considering large 
published series that encompass all ‘ordinary’ BCCs, it seems rather uncommon, oscillating 
from 0.19%  to 0.49% . Some authors reported an increased frequency of 3.8% in cancers 
treated by Mohs’ micrographic surgery (Cernea et al., 2009). 
The cancer may extend cylindrically, several cells thick, around the nevre beneath the 
perineurum (Schwartz, 2008). The low resistance cleavage plane of the perineural sheath 
may allow rapid and broad tumor extension. ‘Skip’ areas along nerves are also common, 
and spread may be proximal or distal along fibers (Walling et al., 2004). 
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Diagnosis of perineural involvement in many cases requires micrographic analysis, as 
patients frequently exhibit no neurological symptoms. Those who do demonstrate sensory 
or motor findings, however, are at particularly high risk of a poor outcome (Walling et al., 
2004). 
Neurotrophic factors that influence the interaction between cancer cells and nerves are 
suspected.  p75NGFR immunostaining increased detection of perineural invasion compared 
with H&E. p75NGFR could serve as an alternative to S-100 in the detection of perineural 
invasion, or as part of an immunostaining panel for  perineural invasion detection (Lewis et 
al., 2006). Usually, however, perineural spread is less extreme but may produce a 
neuropathy. Rarely, the neuropathy may be the presenting sign of a recurrent skin cancer, 
with no cutaneous tumor evident (Morris & Joffe, 1983). Involvement of the trigeminal 
nerve may produce pain; involvement of the facial nerve may cause facial muscle weakness 
(Schwartz, 2008). 
5.3 Metastasis 
Despite the large number of primary BCCs diagnosed each year, the rate of metastatic BCC 
(MBCC) ranges from 0.0028% to 0.5% (Malone et al., 2000 & Soleymani et al., 2008). Since 
MBCC was first reported in 1894 by Beadles, there have been more than 240 cases reported in 
the literature. Of these cases, 66–85% of MBCCs arise from primary lesions in the head and 
neck region (Soleymani et al., 2008 & Ting et al., 2005). 
The primary tumor must originate from the skin and not the mucosa, metastasis must occur 
at a site distant from the primary tumor without evidence of direct extension, and the 
primary and metastatic tumors must have similar  histopathology. These are the criteria 
needed for the true diagnosis of MBCC (Soleymani et al., 2008). Metastases occur in males 
and females in a 2:1 ratio, most often involving dissemination to regional lymph nodes and 
hematogenous spread to lungs, bone, and skin (Ting et al., 2005). 
Risk factors associated with the rare occurrence of metastasis include tumor size of less than 
2cm, multiple primary tumors in the region of the head and neck, significant tumor depth, 
fair skin, middle age, and male gender (Ozgediz et al., 2008). Mean survival for patients 
with metastatic disease is 8 months (Snow et al., 1994), although those with spread limited 
to the lymph nodes alone have an average survival of up to 3.6 years (Soleymani et al., 
2008). 
There is no consensus as to whether any one histologic subtype of the primary tumor 
predisposes to MBCC. Nodular, micronodular, morpheaform, metatypical or basosquamous, 
and infiltrative histologies have all been reported (Soleymani et al., 2008). 
In a retrospective review of 5270 morpheaform or invasive BCCs over a 50-year period did 
not reveal an increased rate of metastasis compared to other histologic subtypes (Soleymani 
et al., 2008). It is very difficult to predict the metastatic potentiality of  BCCs by 
histopathology (Kinoshita et al., 2005). In a case report it was shown that the tumor cells 
were bcl-2 negative and positive for Ber-EP4. The negative expression of bcl-2 correlates 
with the aggressive nature of this tumor and Ber-EP4 confirms the diagnosis of BCC 
(Richard et al., 2010). 
In a literature search of cases of black patients with metastatic BCC revealed eight cases. In 
these cases, the most obvious common predisposing factor seems to be large lesion size, 
with all of the cases having at least one dimension greater than 5 cm (Saladi et al., 2004). 
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6. Diagnosis 
Diagnosis of  BCC is accomplished by accurate interpretation of  the skin biopsy results 
(Carucci, 2008). It should be remembered that the diagnosis of any cancer is always a 
histologic one; clinical acumen cannot replace histologic documentation (Schwartz, 2008). 
The tumor growth pattern is importatnt information that is impossible to determine if only a 
superficial fragment is submitted to the laboratory. Deep shave, punch, incisional or 
excisional biopsy can all give sufficient dermis for the evaluation. 
A number of non-invasive imaging technologies are being investigated to delineate tumor 
depth and extent preoperatively and thus guide treatment. Confocal microscopy, infrared 
spectroscopy and ultrasound are some of them but for the moment they remain 
experimental. 
If a BCC may have been neglected and reached a size such that direct bony invasion 
occurred a preoperative CT scan should be considered. 
Dermoscopy is a noninvasively method that has been reported to be a useful tool for the 
early and accurate recognition of pigmented lesions of the skin . However, nodular lesions 
can lack specific dermoscopic criteria being completely or partially featureless in their 
appearance. Reflectance confocal microscopy (RCM) is an emerging noninvasive diagnostic 
tool that provides in vivo tissue images at nearly cellular histological resolution. In a study 
four patients with  nodular lesions have been examined clinically and dermoscopically 
equivocal a RCM examination allowed for a rapid and accurate prebiopsy diagnosis 
(Carucci, 2008 & Schwartz, 2008). 
7. Differential diagnosis 
A lot of benign appendageal tumors may cause confusion, as may rare malignant 
appendageal cancers, SCCs, atypical fibroxanthomas, melanocytic nevi, Merkel cell 
carcinoma  and rarely melanoma. A hemispheric nodule clinically indistinguishable from a 
BCC may be a trichoepithelioma, a benign appendageal tumor. A small yellowish papule 
with a central dell may be confused with an early BCC; sebaceous hyperplasia is quite 
common and often displays telangiectasia, additionally reminiscent of the BCC. 
Granulomatous lesions  may need a distinction from BCC, examples of which include 
tuberculosis; syphilis; deep fungal infections. Other types of BCC besides the 
noduloulcerative type expand the list of differential diagnoses. Sclerosing-type BCCs may 
be mistaken for scars or small plaques of localized scleroderma (morphea) (Table 1) 
(Schwartz, 2008). 
8. Histopathology 
BCC have in common proliferations of  basaloid keratinocytes in various configurations 
with a variable fibromyxoid stroma. Epidermal origin is usually evident and an 
inflammatory infiltrate is variably present (Miller, 2008). 
Under the microscope, BCC appears as irregular dermal masses of variable sizes and 
shapes, surrounded by a layer of peripheral tumor cells with palisading nuclei. The 
individual tumor cells are usually rather uniform in appearance and lack atypia .When 
nuclear atypia and multiple mitotic figures are rarely present, this does not alter the clinical 
course of these BCCs (Schwartz, 2008). 
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 Nodular basal cell carcinoma:  
o Squamous cell carcinoma 
o Seborrheic keratosis 
o Intradermal nevus  
o Sebaceous hyperplasia  
o Fibrous papule  
o Molluscum contagiosum  
o Keratoacanthoma  
o Scar tissue 
 Superficial basal cell carcinoma:  
o Discoid eczema  
o Psoriasis  
o Actinic keratosis (solar keratosis)  
o Bowen's disease  
o Squamous cell carcinoma  
o Seborrhoeic keratosis  
 Pigmented basal cell carcinoma:  
o Melanoma  
o Lentigo maligna melanoma 
o Appendegeal tumor 
o Compound nevus 
o Blue nevus 
 Morphoeic basal cell carcinoma:  
o Scar tissue  
o Localised scleroderma 
o Trichoepithelioma 
 Fibroepihtelioma of  Pinkus:  
o Skin tag 
o Papillomatous dermal nevus 
o Fibroma 
 
Table 1. Differential diagnosis according to the types of basal cell carcinoma (Carucci, 2008).  
Traditionally, BCCs have been classified as solid (or undifferentiated) vs those tumors that 
manifest specific differentiation features (ie to eccrine, sebaceous or other cell lines). 
However, the only proven histologic prognosticator of biologic behavior, and therefore a 
major determinant of what constitutes an appropriate therapeutic approach, is the 
architectural growth pattern (Crowson, 2006). 
The nuclei in basal cell carcinoma as a rule have a rather uniform, nonanaplastic 
appearance. They usually show no variation in size or intensity of staining and no abnormal 
mitoses, even in the rare instances of  BCC with metastases (Kirkham & Elder 2005). Cellular 
borders are indistinct and desmosomes are inapparent. Apoptotic cells are common. The 
fibromyxoid stroma is intimately associated with the tumor islands, often showing 
increased cellularity (Miller, 2008).  
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8.1 Special types of histological patterns include 
1. Keratotic BCC with parakeratotic stratum corneum 
2. Sebaceous differentiation of the sebaceous epithelioma (also called BCC with sebaceous 
differentiation, a possible marker for Muir-Torre Syndrome of multiple sebaceous 
neoplasms, keratoacanthomas, and multiple low-grade visceral malignancies)  
3. Adenoid histologic-type BCC, with its lace-like pattern of interconnected tumor strands, 
producing a glandlike structure 
4. Sclerosing BCC with abundant dense stroma with multiple islands of compressed 
tumor cells  
5. Pigmented BCC with histologic evidence of melanocytes with large amounts of melanin 
6. Superficial-type BCC with superficial tumor buds that appear to originate at multiple 
foci from the overlying attached epidermis 
7. Fibroepithelioma, with its long, thin anastomosing tumor cell strands  
8. Granular cell–type BCC  
9. Signet-ring–type BCC  
10. Clear cell–type BCC  
11. Cystic BCC, which may mimic other cysts, including inclusion cysts due to penetrating 
injury, mucoceles, apocrine hidrocystoma, and necrotic metastatic tumors 
12. BCC with eccrine differentiation  
13. MTC with tumor lobules more irregular and peripheral palisading less pronounced but 
focally present. Stromal proliferation is more prominent. 
Areas of typical BCC may be seen to merge into a metatypical region. The most important 
histologic finding that confirms the metatypical carcinoma (MTC) diagnosis is the absence of 
a transition zone between the basal cell and squamous cell types. This is the reason why 
MTC is not a collision between a BCC and a SCC (Kirkham & Elder 2005; Schwartz, 2008). 
8.2 Nodular Basal Cell Carcinoma 
The nodular form of BCC is characterized by discrete large or small nests of basaloid cells in 
either the papillary or reticular dermis accompanied by slit-like retraction from a stroma in 
which the fibroblasts do not appear to be plump or proplastic . Any of the differentiated 
elements (eccrine, sebaceous, etc) may be seen in nodular tumors and roughly one-third of 
cases will show a coexistent superficial component. 
The surrounding stroma shows myxoid change, is rarely fibrotic and may show calcification 
in discrete islands of tumor or in adjacent stroma. Mitoses and individual cell necrosis are 
uncommon. The presence of abundant slit-like retraction may cause tumor nests to drop out 
from the stroma during processing yielding empty spaces with a rounded contour in the 
mid or deep dermis. This is an important clue to the diagnosis in the setting of the nodular 
and/or infiltrative growth patterns. A significant proportion of BCCs with a nodular 
component manifests a variable admixture of superficial and/or micronodular 
morphologies. Melanin pigmentation of tumor cells and adjacent stromal histiocytes may be 
seen (Crowson, 2006). 
In larger tumor islands, central areas of necrosis may develop, leading to the formation of 
cystic spaces. True cystic or nodulocystic BCCs form on the basis of mucin pools within 
tumors (Miller, 2008). 
8.3 Micronodular Basal Cell Carcinoma  
Micronodular BCC manifests a plaque-like indurated lesion with a poorly demarcated 
contour. They are composed of smaller tumor islands than those of nodular BCC. The 
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cellular features are similar (Miller, 2008). The micronodular BCC has been reported to have 
a higher incidence of local recurrence and may penetrate more deeply into the reticular 
dermis and/or subcutis (Crowson, 2006). 
8.4 Infiltrative growth Basal Cell Carcinoma  
Infiltrating BCC is poorly circumscribed with jagged, irregular contours and tumor strands 
which may invade beyond the dermis. Peripheral palisading is absent, inflammation is 
minimal, and the surrounding stroma is often fibrous. There is evidence that many of these 
multifocal buds connect in a net-like pattern, so most are not truly multifocal (Miller, 2008). 
Infiltrative tumors, in particular, have been found to have a relatively higher growth 
fraction as ascertained by Ki-67 immunohistochemistry (Walling et al., 2004). 
8.5 Keratotic Basal Cell Carcinoma  
Also known as pilar BCC as it appears to differentiate along pilosebaceous lines, the 
keratotic BCC manifests large basaloid tumor nests that are rounded and show central 
keratinization and degeneration. The central cysts typically lack a granular cell layer and 
are filled with keratin and parakeratotic debris; a granular cell layer is present in some 
cases and the cysts may show central calcification surrounded by the basaloid tumor 
cells.True hair production is absent (Crowson, 2006). Infundibulocystic BCC may appear 
similar but usually has a more anastomosing pattern of tumor nets (Miller, 2008). 
Keratotic BCC shares with trichoepithelioma the presence of horn cysts, and it is 
sometimes difficult to decide whether a lesion represents a keratotic BCC or a 
trichoepithelioma (Kirkham & Elder 2005). 
8.6 Morpheaform Basal Cell Carcinoma 
Morpheaform or sclerosing BCC is characterized by columns of  basaloid cells one to two 
cells thick enmeshed in a densely collagenized stroma containing proplastic fibroblasts 
(Crowson, 2006). A peripheral palisaded pattern of tumor cells is absent and stromal 
retraction is also frequently not evident (Miller, 2008 ; Walling et al., 2004). Individual cell 
necrosis and mitotic activity considering the relative tumor volume and the neoplasms 
themselves are poorly demarcated, showing widespread invasion of the reticular dermis 
and penetration into the subcutaneous tissue (Crowson, 2006). Morpheaform BCC has been 
associated with greater subclinical depth of extension , and morpheaform and infiltrating 
BCC are associated with a greater rate of recurrence (Walling et al., 2004).  
8.7 Fibroepithelioma of Pinkus 
Described by Pinkus in 1953 the fibroepithelioma typically arises above the natal cleft or on 
the lower trunk as a pink or flesh colored nodule with a constricted inferior margin 
suggesting a seborrheic keratosis. In this tumor, elongated basaloid epithelial strands 
manifesting slit-like retraction from stroma are enmeshed in a myxoid matrix or a 
background of proliferating spindle cells with abundant collagen (Crowson, 2006 & Miller, 
2008). Peripheral palisading is less prominent, as is peritumoral retraction. 
Only rarely will one find areas of the tumor with more classic findings for BCC. Some 
consider fibroepithelioma as a benign tumor while others view it as very low-grade of BCC 
(Braun-Falco et al., 2000). In differential diagnosis ecrine syringofibroadenoma and 
reticulated seborrheic keratosis should be considered (Miller, 2008). 
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8.8 Subtypes according to histopathological growth pattern and potential for 
aggression 
Less aggressive 
 Superficial 
 Nodular 
More aggressive 
 Infiltrative 
 Micronodular 
 Morphoeic 
Other types (uncommon) 
 Basosquamous (metatypical) – BCC with squamous differentiation. Probably more 
aggressive with a greater chance of metastasis than other forms of BCC. 
 Adenoid 
 Cystic 
 Pigmented 
 Cornifying/keratotic 
 Fibroepithelioma 
 Follicular/infundibulocystic 
9. Treatment 
For basal cell carcinoma, the goal of treatment is elimination of the tumor with maximal 
preservation of function and physical appearance according to the 2011 National 
Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. As such, 
treatment decisions should be individualized according to the patient's particular risk 
factors and preferences. Evaluating all of the cases, the recommended treatment modality 
for basal cell carcinoma is surgery. Treatments vary according to cancer size, depth, and 
location on the body. Dermatologists may perform nearly all of the therapeutic options in an 
outpatient setting. Most therapies are well established and widely applied; nevertheless, 
researchers are studying some additional options (photodynamic therapy with 
photosensitizers etc and awaiting further reports.  
Local therapy with chemotherapeutic and immune-modulating agents is useful in some 
cases of BCC. In particular, small and superficial BCC may respond to these compounds. 
Topical 5% imiquimod is approved by the US Food and Drug Administration (FDA) for the 
treatment of nonfacial superficial BCCs that are less than 2 cm in diameter. Likewise, topical 
fluorouracil is approved by the FDA for the treatment of superficial BCC.   Both imiquimod 
and fluorouracil may be used topically for prophylaxis or maintenance in patients who are 
prone to having many BCCs.  
For tumors that are more difficult to treat (infiltrative, morpheaform, micronodular, and 
recurrent BCCs) or those in which sparing normal (noncancerous) tissue is paramount, Mohs 
micrographic surgery should be preferred.  
For metastatic BCC, the 2011 NCCN guideline recommends clinical trials of systemic 
chemotherapy, particularly platinum-based combination therapy. Clinical trials of 
investigational biologic modifiers such as hedgehog pathway inhibitors are also 
recommended (Bader, 2011). 
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9.1 Mohs Micrographic Surgery  
Mohs micrographic surgery (MMS) is a procedure based on the principles of microscopic 
margin control and tissue sparing (Alam et al., 2010). Mohs micrographic surgery was first 
reported in 1941 by Mohs (Samarasinghe et al., 2011). At first the tumor tissue is removed at 
an angle of about 45º, and then tumor tissue is instantly frozen and cut horizontally from the 
base to the surface, and all margins, especially lateral and basal margins, examined 
histologically whether tumor cells are still present or not. If the tumor cells detected, 
additional excisions are performed until all the tumor tissue has been disappeared (Wetzig 
et al., 2009). This method almost requires local anesthesia (Telfer et al., 2008). 
This specialized surgical procedure is commonly used in a patient with large (> 2 cm) 
tumors, high-risk morphea-type BCC tumors, recurrent tumors, or tumors located in 
cosmetically sensitive locations (Ceilley Del & Rosso, 2006). There are three important 
matter for compliance with the method of Mohs micrographic surgery for BCCs: i) location 
and size, ii) histology, iii) pre-treatment preferences. If BCC lesion is located on the head and 
neck, if some of the histological types are present (shown in Table 2) and if the lesion is 
previously untreated, MMS is preferable. The most common indication for MMS is BCC 
located on the head and neck. Because these sites of the body are the most cosmetically 
sensitive regions and also recurrence risk is considerably high. BCC lesions in some parts of 
the body such as eyelids, lips, ears, nose, H-zone, genitalia, fingers and toes are generally 
treated by Mohs micrographic surgery (Wood & Ammirati, 2011). Aggressive histological 
subtypes of BCC include metatypical, morpheaform, micronodular, and infiltrative have a 
higher risk for recurrence, for this reason MMS is recommended in the treatment of these 
lesions with this certain histology (Cumberland, 2009). The indications for Mohs 
micrographic surgery are shown in Table 3 (Telfer et al., 2008). 
Most of the methods of treatment except MMS do not include microscopic evaluation of 
tumor margins, such as curettage and desiccation, cryosurgery, radiation therapy and 
topical chemotherapy (Cumberland, 2009). The advantages over other surgical procedures 
this surgical procedure enables for greater tissue conservation and margin control (Ceilley 
Del & Rosso, 2006). Muller and his colleagues have shown that MMS is more tissue sparing 
compared to surgical excision (Muller et al., 2009). Also the 5- year recurrence rate is 
approximately 1% and 6-10% for primary BCC and recurrent BCC, respectively (Ho & 
Byrne, 2009). In another study conducted in recent years, very low recurrence rates and 
excellent cure rates have been reported in both primary and recurrent BCC by Wetzig et al 
(Wetzig et al., 2010).  
 
 BCC with poorly defined clinical margins 
 Syndromic multiple BCCs  
 Large and deeply penetrating BCC 
 Basosquamous (metatypical) BCC 
 Morphea-form, sclerotic, micronodular, infiltrative, recurrent BCC 
 BCCs with local invasion (perichondral, perivascular, periosteal, and perineural 
invasions) 
 Superficial multicentric BCC 
 BCC arising within a scar 
 BCC within an existing lesion 
Table 2. MMS is preferred in the treatment of some specialized subtypes (Wood & 
Ammirati, 2011). 
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In recent years, high-resolution ultrasound has been used for some tumoral lesions before 
Mohs micrographic surgery and is indicated for small lesions of BCC (Marmur et al., 2010). 
It is a non-invasive technique and it can detect how deep tumors spread into the skin (Wood 
& Ammirati, 2011).  
Also in recent years immunostaining techniques have been used to detect tumor cells when 
histological features are nonspecific or is masked histologically by dense inflammation. 
Sometimes immunostaining can increase the efficacy of the margins evaluation but it is very 
expensive (Cumberland, 2009). 
Complications of Mohs micrographic surgery include postoperative bleeding, scarring, 
wound infection, flap or graft necrosis (Samarasinghe et al., 2011). 
 
 Tumor site cosmetically sensitive locations (especially central face, around the eyes, 
nose, lips and ears) 
 Undefined tumor margins 
 Tumor size (any size, but mainly > 2 cm) 
 Histological subtype (especially morpheaform, infiltrative, micronodular and 
basosquamous subtypes) 
 Recurrent lesions 
 Local invasions (perineural or perivascular involvement) 
Table 3. Indications for Mohs micrographic surgery (Telfer et al., 2008). 
9.2 Standard surgical excision 
Surgical excision is the main treatment modality for basal cell carcinoma and is usually 
applied as a standart method (Rogers & Bentz, 2011). This method is one of the most 
commonly used techniques in the treatment of nodular BCC and superficial BCC. Tumor 
tissue plus surrounding normal tissue area should be excised in this method (Ceilley Del & 
Rosso, 2006). A four millimeter excision margin is currently recommended for small, well 
demarcated BCC’s (Sherry et al., 2010). The deep margins should contain the fascia 
(forehead), the perichondrium (ear, nose), or the periosteum (scalp) (Dandurand et al., 
2006). Then, whether the presence of tumor cells in extracted material margins, should be 
verified by histopathological examination. Nevertheless, the incidence of incomplete 
excision can be increased up to 10% approximately. Some factors such as experience of 
surgeon, histologic subtypes and excision margins play an important role in the success of 
the operation (Ceilley Del & Rosso, 2006). 
Its effectiveness is quite higher for primary BCC and also cosmetic results are usually well. 
Peripheral excision margins for primary BCC of 3–5 mm and 5-10 mm for recurrent BCC 
have been suggested. Due to high recurrence risk excision should be wider in recurrent BCC 
(Telfer et al., 2008). In contrast to small primary BCCs, morphoeic and large BCCs require 
wider surgical margins, between 5-15 mm, for complete histological resection (Pua et al., 
2009). Gulleth et al. reported that 3-mm surgical margin can be safely used for 
nonmorpheaform basal cell carcinoma lesions 2 cm or smaller (Gulleth et al., 2010). 
The cure and recurrence rates are variable. Wetzig et al. reported high cure rates for primary 
and recurrent BCCs, 99,5% and 97,1% respectively, at the end of 5-year follow-up (Wetzig et 
al., 2010). Szeimies et al. reported that clinical lesion response 99,2% and cosmetic outcome 
59,8% 3 months and 12 months after surgical excision for superficial basal cell carcinoma, 
respectively. 12 months after surgical excision, reccurence has not been reported (Szeimies et 
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al., 2008). Rhodes et al. found that surgical excision is more effective than photodynamic 
therapy for the treatment of nodular basal cell carcinoma as a result of 5-year follow-up and 
recurrence rate was reported as 4%. (Rhodes et al., 2007). In 2008 a randomised controlled 
study of surgical excision versus fractionated 5-aminolevulinic acid-photodynamic therapy 
by Mosterd et al. found that 88 primary nodular BCC excised with 3 mm margins, the 
cumulative incidence of failure was 2,3% after 3-years of treatment (Mosterd et al., 2008). 
There are some disadvantages of this method such as scars, bleeding and risk of infections 
(Szeimies et al., 2008). Also incomplete excision is another complication of the surgical 
excision which is correlate with the cure and recurrence rate, the patients morbidity and/or 
mortality, and the overall cost of treatment. Pua et al. reported that the overall incomplete 
excision rate was 1,54% (Pua et al., 2009). For this reason, surgical excision should be done 
by experienced surgeons (Szeimies et al., 2008). 
9.3 Chemotherapy 
Chemotherapy is generally used in two conditions: i) for the management of uncontrolled 
local disease, ii) for patients with metastatic BCC. Both conditions are extremely rare and are 
rapidly fatal position. 
Various drugs can be used in metastatic BCC, including cyclophosphamide, etoposide, 5-
fluorouracil, methotrexate, bleomycin, doxorubicin, and cisplatin but their effectiveness is 
variable. Cisplatin is the most effective chemotherapeutic agent in the treatment for patient 
with metastatic or locally advanced BCC, alone and/or combined. Carneiro et al. reported 
that a case of BCC metastatic to the lungs treated with the combination of carboplatin and 
paclitaxel (Carneiro et al., 2006). Also Jefford et al. observed that this treatment regimen was 
less neurotoxic effect and could provide rapid symptomatic relief (Jefford et al., 2004).  
Paclitaxel, which is a chemotherapeutic agent, shown to be effective in a patient with nevoid 
BCC syndrome. Most of the aggressive BCC lesions of the patient which had not responded 
to treatment with intravenous cisplatin healed after 19 cycles intravenous paclitaxel 
treatment (Russo, 2005). 
Snipes et al. reported that there was improvement with systemic 5-fluorouracil(5-FU) in a 52-
year-old male patient with nodular BCC (Snipes et al., 2006). 
9.4 Curettage and desiccation 
Electrodesiccation and curettage (ED&C) is the most common method used by 
dermatologists to treat primary nodular and superficial BCC tumors < 1,5 cm in diameter 
(Ceilley Del & Rosso, 2006; Jefford et al., 2004). Initially tumor tissue is curetted and then the 
area is treated with electrosurgery (electrodesiccation or coagulation) to control bleeding 
until clinically normal tissue is appeared and all of tumor cells are eliminated. This method 
is repeated two or three times for achieving the success (Ceilley Del & Rosso, 2006). The 
wound heals within 4-6 weeks by secondary intention (Ho & Byrne, 2009). 
While electrodesiccation and curettage are generally used for the treatment of low-risk 
lesions, they are generally contraindicated for the treatment of high-risk lesions because of 
their high recurrence risk (Telfer et al., 2008). This method can be applied in selected cases 
whom patients with multiple, superficial tumors on the trunk. Nevertheless, this method is 
contraindicated for facial tumors and in high-risk lesions (Wetzig et al., 2009). 
Disadvantages of this treatment option include to leave residual tumor tissue which may be 
demonstrated with histopathological examination and to develop hypertrophic scarring at 
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lesion site (Wu et al., 2006). There is a risk of development of hypertrophic scarring or white 
scar tissue formation after the procedure and this probability increases with the number of 
treatment cycles (Ceilley Del & Rosso, 2006). Some complications such as ulceration, 
hypopigmentation, blistering, edema, pain, secondary infection and recurrence can be seen 
immediately after the  treatment or a later period (Dixon, 2005). Despite all of these 
possibilities cosmetic outcomes are usually pleasurable (Murchison et al., 2011). 
The cure rates for primary basal cell carcinoma were reported between 88%-99% (Murchison 
et al., 2011). Also Barlow et al. reported that results of curettage alone were successful for 
nonaggressive basal cell carcinomas (Barlow et al., 2006). 
9.5 Cryosurgery 
The aim of this method is destruction of tumor cells using liquid nitrogen spray or probe. 
Cryosurgery is usually suitable for BCC lesions with well-defined borders (Ceilley Del & 
Rosso, 2006). Liquid nitrogen has a boiling point of -195ºC, making it a very effective 
cryotherapy agent (Moesen et al., 2010). Two freeze-thaw cycles (30 seconds each cycle 
duration) with a tissue temperature of -50 ºC are recommended (Ceilley Del & Rosso, 2006). 
While double freeze-thaw cycles are generally suggested for the treatment of facial BCC, 
superficial truncal lesions may need only one treatment cycle (Telfer et al., 2008). At first the 
diagnosis should be confirmed by biopsy. Preliminary curettage may be done before 
cryosurgery except superficial basal cell carcinoma. Thermocouple needles are useful to 
measure the temparature inside the tumor. When the desired temperature was achieved 
within the tumor, freezing process is interrupted until the frozen ring is resolved, and then 
freezing-thawing cycle was repeated (Kuflik, 2004). The success rate increases when the 
procedure used the treatment of correct lesions by the experienced people (Telfer et al., 2008). 
One of the advantage is that this method does not require local anesthesia. Other advantages 
are outpatient, inexpensive and no requirement of patient sedation (Murchison et al., 2011).   
Some factors include rate of temperature fall, speed of tissue thaw, solution concentration, 
time of subzero temperature exposure, lowest temperature achieved in the target tissue and 
the number of freeze–thaw cycles can change the degree of tissue destruction. If the freezing 
occurs quickly, further tissue damage happens according to slow freezing (Murchison et al., 
2011). 
Two distinct technique, open also known as spray and closed also known as probe or 
contact, are preferred for malignant lesions. Some sensitive areas, e.g. eyelids, the use of 
probes is quite favorable, because periocular structures can be damaged with spray 
technique. Therefore, when using the spray technique, it should be noted to avoid damage 
to unaffected areas by the dermatologists (Murchison et al., 2011). In the treatment of 
primary periocular BCCs, cryosurgery with nitrous oxide probe may be an alternative 
treatment modality in the absence of appropriate surgical procedures. The disadvantage of 
this procedure is higher recurrence rate, approximately 8%, compared with other treatment 
modalities (Moesen et al., 2010). But Emanuel and her colleagues reported that 5-years cure 
rate and 30-years cure rate for basal cell carcinoma after cryosurgery were 99% and 98,6% 
respectively (Kuflik, 2004). This noninvasive method was compared with topical methyl 
aminolaevulinate photodynamic therapy, recurrence rates were similar but cosmetic results 
were worse than photodynamic therapy (Basset-Seguin et al., 2008). 
Adverse events such as peri/postoperative pain, tenderness, vesicle and/or bullae, 
erythema, sloughing of necrotic tissue or eschar formation, localized edema, scarring, 
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hypo/hyperpigmentation may occur during or after the procedure (Ceilley Del & Rosso, 
2006). Posttreatment pain may require the use of narcotic drugs especially within the first 
few days (Murchison et al., 2011). Severe edema may occur in some locations such as 
periorbital region, around the temples and on the forehead and therefore the patients should 
be warned (Wetzig et al., 2009). 
Cryosurgery should be avoided in areas of hair growth and in patients with conditions 
sensitive to temperature, including Raynaud’s syndrome, cold panniculitis, and 
cryoglobulinemia (Ceilley Del & Rosso, 2006). Some body sites such as hair-bearing scalp, 
nasolabial fold, tragus, retroauricular groove, upper lip and distal portion of the lower leg 
are relatively contraindicated locations. Cryotherapy is not recommended for 
sclerodermiform BCC (Wetzig et al., 2009). 
9.6 Topical treatment of Basal Cell Carcinoma  
9.6.1 Imiquimod cream 
Topical imiquimod 5% cream (Aldara 3M Pharmaceuticals, St Paul, MN) is a Toll-like 
receptor agonist that acts as an immune-response modifier (Raasch, 2009 & Robinson et al., 
2003). Imiquimod 5% cream is approved by the United States Food and Drug 
Administration (FDA) for the treatment of external genital and perianal warts; 
nonhyperkeratotic actinic keratosis and superficial BCCs mostly in patients in whom 
surgery is not an option. Imiquimod promotes the innate immune response and the cell-
mediated immune pathway, potentiating its antiviral, antitumoral, and immunoregulatory 
properties (Amini et al., 2010). The mechanism of action of imiquimod is thought to occur 
through the binding to cell surface receptors, such as Toll-like receptor 7 which leads to 
activation of macrophages and other cells (Ceilley Del & Rosso, 2006). Toll like receptor 7 
(TLR-7) is found on dendritic cells and monocytes (McGillis & Fein, 2004). Binding to TLR-7 
receptor induces proinflammatory cytokine secretion (e.g.interferon-alpha and tumor 
necrosis factor-alpha, IL-1, IL-12, IL-6, IL-8, and IL-10) that favors type 1 helper T-cell-
mediated immune response (Robinson et al., 2003). These cytokines play role in the 
activation of the adaptive immune response toward the TH-1 or cell-mediated pathway and 
inhibit the TH-2 pathway. By this immunmodulation, imiquimod is believed to be 
important for control of tumors (Navi & Huntley, 2004). Data have shown that imiquimod 
5% cream may induce Fas (CD95) receptor (FasR) mediated apoptosis in BCC cells (Berman 
et al., 2003).  Normally in BCC cells  FasR expression is not seen  so cell apoptosis via a 
FasR–Fas ligand interaction is prevented (Ceilley Del & Rosso, 2006). Berman et al. 
demonstrated that BCC cells in 3 of 4 patients treated with  imiquimod 5% cream applied 
five times per week for up to 2 weeks were positive for FasR, leading to an infiltration of T 
lymphocytes (i.e. suggesting cell apoptosis), while all 5 vehicle-treated patients had FasR 
negative BCC cells at the end of the treatment period (Berman et al., 2003).  Therefore, 
imiquimod 5% cream acts by inducing FasR in the treatment of BCC.  
Imiquimod has been approved in the United States by the FDA for the treatment of 
superficial BCC (sBCC) in immunocompetent adults with tumors >0.5 cm2 in area and <2 
cm in diameter located on the trunk and extremities (Krown, 1991). Initial trials of 
imiquimod 5% cream for the treatment of skin cancer focused on sBCC. In a multicenter 6-
week dose-response trial, complete histological clearance was seen in  87.9 % (29/33) of 
patients in the once-daily three-times-per–week regimen, 73.3 % (22/30) of patients in twice-
daily three-times-per-week regimen, and 69.7 % (23/33) of patients in the once-daily, three-
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times-per-week regimen. The median duration of treatment for complete clearance was 10-
16 weeks (Marks et al., 2001). 
Patients with sBCC were enrolled in a randomized, double-blind,vehicle-controlled study to 
determine the efficacy of longer treatment regimens and treated with imiquimod for 12 
weeks once daily seven times per week (n =31), once daily five times per week (n =26), or 
once daily three times per week (n =29) (Geisse et al., 2002). In this study, histologic 
clearance rates in the three groups were 87%, 81%, 52%, respectively. These histologic 
clearance rates for imiquimod were similar to those reported in the 6-week study (Marks et 
al., 2001), suggesting that an additional 6 weeks of treatment may not be necessary for 
efficacy. 
In addition to sBCC, imiquimod also has been demonstrated efficient in the treatment of 
nBCC (Shumack et al., 2002). One such study was a Phase II clinical trial comparing efficacy 
of various dosing regimens in a 6-week study in Australia and New Zealand and a 12-week 
study in United States. In both studies histological examination of lesion site on 6-weeks 
post-treatment showed the highest clearance rate in the once daily for 7 days per week 
groups, with 71% of patients in the 6-week study and 76% of patients in the 12-week study 
having complete response following treatment. The authors pointed out that these response 
rates were lower than the nearly 88% response rates seen in studies of superficial BCC 
lesions (Shumack et al., 2002).This type of treatment modality applies better for those 
patients in which surgery, radiotherapy, or cryotherapy are not an option. 
The side effects from use of imiquimod are mainly local site reactions. In a phase II study, 
the most common local skin reactions were erythema, crusting, flaking, and erosion (Marks 
et al., 2001). However, these dose-related side-effects were generally well tolerated, and 
none of the patients discontinued because of local skin reactions. 
In addition to monotherapy, imiquimod 5% cream may also be useful as adjunctive therapy 
in the treatment of BCC. Torres et al. have reported on a randomized, double-blind, vehicle-
controlled phase II study (n = 72) of imiquimod 5 days per week for 2–6 weeks before 
excision with MMS in the treatment of sBCC and nBCC. Treatment with imiquimod 
significantly reduced the size of the target tumor and thereby resulted in a smaller cosmetic 
defect from the MMS excision compared with vehicle (Torres et al., 2003). 
9.6.2 Topical 5- Fluorouracil 
Fluorouracil (5-FU) is an antineoplastic pyrimidine analog which decreases cell proliferation 
and induces cellular death, particularly in cells with high mitotic rates, through inhibition of 
thymidylate synthetase, which interferes with DNA synthesis. Evidence suggests that 5-FU 
used as a topical chemotherapeutic agent in NMSC has been effective for the treatment of 
superficial BCC, insitu SCC, and AKs. Due to lack of penetration through the dermis, 5-FU 
is generally not recommended for invasive BCCs and SCCs (Chakrabarty & Geisse, 2004). 
Published studies have indicated that 5-FU monotherapy has low clearance rates compared 
with other modalities. In a small study, 44 sBCC tumors were treated with a high 
concentration of medication, administered as a 25% fluorouracil paste, with occlusion that 
was changed once weekly for 3 weeks (Ebstein, 1985). This treatment regimen resulted in a 
5-year recurrence rate of 21%. Although rigorous data are lacking, reports of 5-FU in 
combination with curettage or cryotherapy have suggested that combination therapy may 
be more effective than monotherapy (Ebstein, 1985; Tsuji et al., 1993). In the same study, 51 
light curettage of 244 sBCC tumors before the 25% fluorouracil regimen resulted in a 5-year 
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cumulative recurrence rate of 6%, compared with the above-noted 21% for the fluorouracil 
regimen alone. Because limited data are available, the actual clearance rate for the topical 
treatment of sBCC with 5-FU is currently unknown. 
In another study,superficial BCC treated with fluorouracil, thirty-one tumors were treated 
twice daily for an average of 11 weeks. A 90% clearance rate was observed on the basis of 
histologic evaluation results 3 weeks after treatment. No clinical follow-up was provided 
(Gross et al., 2007). 
Application of 5-FU causes severe local skin reactions, including pain and burning, pruritus, 
irritation, inflammation, swelling, tenderness, hyperpigmentation, and scarring (Ebstein, 
1985). 
9.7 Radiation Therapy 
Radiation therapy (RT) has been a useful alternative to surgical treatments. Radiotherapy 
(RT) can be effective for primary BCC, recurrent BCC or as adjuvant for incompletely 
excised BCC in patients where further surgery is neither possible nor appropriate 
(Samarasinghe et al., 2011). It has been particularly useful in the treatment of elderly 
patients and for larger tumors or tumors in difficult-to treat locations, such as the eyelids or 
pinna of the ear. Lower risk areas, such as the trunk and extremities, as well as the genitalia, 
hands, and feet are usually not treated with this modality (Ceilley Del & Rosso, 2006). RT is 
a complex mixture of different techniques including superficial RT (generated at up to 170 
kV) which is suitable for lesions up to ~6 mm in depth, electron beam therapy (generated at 
higher energies) which penetrates deeper tissues, and brachytherapy which is useful for 
lesions arising on curved surfaces (Telfer et al., 2008). The total dose and treatment regimen 
(e.g. number of fractionated doses) depend on many factors including tumor location, size, 
type, and depth (Ceilley Del & Rosso, 2006).  Radiotherapy is contraindicated in 
radiotherapy recurrent BCC, genetic syndromes predisposing to skin cancer and connective 
tissue disease. Significant side effects are radionecrosis, atrophy, and telangiectasia. Skin 
cancers can arise from radiotherapy field scars and should be avoided in younger age 
groups (Samarasinghe et al., 2011).  
A study of BCC irradiated by a ‘standardized’ X-ray therapy schedule indicated an overall 
5-year recurrence rate of 7.4% for primary (n =862) and 9.5% for recurrent (n =211) BCC 
(Silverman et al., 1992). 
Surgical excision (91% with frozen section margin control) of 174 primary facial BCCs < 4 
cm in diameter has been compared with RT (mix of interstitial brachytherapy, contact 
therapy and conventional RT) for 173 lesions (Avril et al., 1997).  The 4-year recurrence rates 
were 0-7% (surgery) and 2-5% (RT). 
Radiation therapy is contraindicated in certain genetic disorders, which predispose patients 
to skin cancers (e.g. patients with Gorlin’s syndrome, xeroderma pigmentosum, or 
connective tissue diseases, such as lupus and scleroderma) (Ceilley Del & Rosso, 2006). 
9.8 Photodynamic Therapy 
Photodynamic therapy (PDT) is performed by topical application of the prodrug 5-
aminolaevulinic acid (ALA) or methyl aminolaevulinic (MAL) to the BCC lesion. The 
prodrug is converted intracellularly into a potent photosensitizer, protoporphyrin IX (PpIX), 
and, when exposed to oxygen and an appropriate light source, a cytotoxic reaction via 
oxygen radicals occurs within cells containing these precursors.(Ceilley Del & Rosso, 2006; 
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Samarasinghe et al., 2011).  The light source is usually either 410nm blue light or 630nm red 
light to match the absorption peak for PpIX. Red light may be preferred with the lipophilic 
MAL for deeper tissue penetration (Samarasinghe et al., 2011). PDT induces intense 
inflammation through the release of cytokines, chemokines and other immunological 
proteins by the injured and apoptotic cells. PDT has also been demonstrated to act as a 
biologic response modifier (Oseroff, 2006). In addition to damaging target cells directly, 
PDT, through upregulated cytokine production, enhances the innate and adaptive immune 
responses in immunocompetent individuals (Oseroff, 2006). 
In a study of 95 patients with sBCC, the primary response rate with ALA PDT was 86%, 
with a 44% recurrence rate after a median follow up of 19 months and a projected disease-
free rate of only 50%  (Fink-Puches et al., 1998). In a long-term study of 350 sBCC and nBCC 
lesions treated with methyl 5-ALA PDT, 89% of lesions cleared with an overall cure rate of 
79% after a mean follow-up of 35 months (Soler et al., 2001). 
For nodular BCC a study comparing MAL PDT with surgical excision in 101 patients 
showed a MAL PDT cure rate of 76% compared to 96% for surgical excision. Cosmetis result 
was better for PDT with 87% of patients rated as good cosmetic outcome in comparison to 
54% for surgery (Rhodes et al., 2004).  
When undergoing PDT, patients often complain of stinging, burning, and itching at the site 
of treatment. Erythema, scaling, and crusting may be evident after treatment, but usually the 
area heals with no evidence of scarring (Neville et al., 2007).  
Although one advantage of PDT is that multiple BCC tumors can be treated simultaneously, 
PDT is a relatively inconvenient treatment option. Treatment involves a two stage process 
requiring several office visits. Because single PDT treatment demonstrates poor efficacy in 
BCC, multiple visits to a healthcare provider’s office are required. Photosensitivity is also 
associated with this treatment regimen. After application of topical agents, patients should 
avoid exposure to sunlight or bright indoor light until after controlled exposure to the light 
source that completes treatment. Treatment with PDT is contraindicated in patients with 
porphyria, known allergies to porphyrins, and patients with photosensitivity to wave 
lengths of applied light sources (Ceilley Del & Rosso, 2006). 
9.9 Immunotherpy 
9.9.1 Intralesional Interferon 
Interferon (IFN) works by binding to receptors located on target cells. The exact mechanism 
of action of these cytokines remains unclear, but interferons are known to have many 
important effects for the treatment of skin cancer, including antiproliferative effects (i.e., 
inhibition of mitosis and growth factors, activation of pro-apoptotic genes, and promotion of 
antiangiogenic activity) and upregulation of the immune system in the skin (Amini et al., 
2010).  
The mechanism by which IFN causes regression of BCCs has also been investigated. In IFN-
treated BCCs, a considerable increase in the number of CD41 T cells infiltrating the dermis 
and surrounding the BCC nests was observed. As CD41 T cells have been shown to be 
capable of inducing apoptosis in their target cells via the CD95 receptor–CD95 ligand 
interaction, the expression of this ligand and receptor was subsequently analyzed in IFN-
treated BCCs. In untreated patients, BCCs were found to express the CD95 ligand but not 
the receptor. In IFN-treated patients, BCCs expressed both the CD95 ligand and CD95 
receptor, indicating that this signaling pathway may be capable of inducing apoptosis 
within these tumors by CD95 interactions with CD95 ligand  (Buechener et al., 1997). 
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Intra- and perilesional IFN represent effective nonsurgical alternatives to treat BCCs, 
obtaining clearance rates between 70 to 100% (Telfer et al., 1999; Tucker et al., 2006). Its use 
is limited by its cost, safety profile, and the inconvenience of returning to a physician’s office 
for multiple injections. A multicenter randomized controlled trial where IFN-α2b was used 
to treat 172 patients with biopsy proven BCC found the optimal dose to be 1.5 million IU 
intralesionally administered 3x/wk for three weeks. Significant clinical and histological 
clearance was obtained when compared with placebo (Greenway et al., 1986).  
Twenty BCCs received treatment with intralesional IFN-α2b 3x/wk for three weeks at a 
dose of 1.5 million IU for lesions less than 2cm in diameter and three million IU for lesions 
2cm or greater in diameter. More than half of lesions completely responded clinically and 
histologically at eight weeks of follow up. In those lesions that completely responded, only 
one recurrence was reported at five years of follow up (Bostanci et al., 2005).  
Treatment with IFN can cause flulike symptoms including headache, myalgia, and fever, 
which can be alleviated by taking acetaminophen (Neville et al., 2007). 
Even though several studies have demonstrated IFN’s biologic potential for the treatment of 
BCC, it is not an established treatment option for BCC. This is because the clearance rates 
(approximately 70%) do not approach those achieved with surgical interventions, and it is 
also time consuming and costly to perform, as injections have to be administered by a 
healthcare professional up to five times per week. In addition, there have been no definitive 
large-scale studies that have determined the initial and long-term efficacy of this treatment 
option (Gaspari & Sauder, 2003). 
9.10 Special management issues 
9.10.1 Incompletely Excised Basal Cell Carcinoma 
Various prospective and retrospective reviews of incompletely excised BCC suggest that not 
all tumours will recur. Studies using approximately 2–5 years of follow up have reported 
recurrence rates following histologically incomplete excision of 38%, (Richmond & Davie, 
1987) and 41% (De Silva & Dellon, 1985). Patients should undergo re-treatment of 
incompletely excised lesions  especially when they involve critical midfacial sites, where the 
deep surgical margin is involved, the surgical defect has been repaired using skin flaps or 
skin grafts and where histology shows an aggressive histological subtype (Mackie & Quinn, 
2004).   If the decision is made to re-treat rather than observe, re-excision (with or without 
frozen section control) or MMS are the treatments of choice. Patients should be treated at the 
time of diagnosis, because delay will likely result in increased local tissue damage. Patients 
should be evaluated for XRT if they are unable to undergo re-excision (Carucci & Leffell, 
2008). 
9.10.2 Neurotropic Basal Cell Carcinoma  
Perineural invasion is not a common finding in basal cell carcinomas, with an estimated 
incidence that, depending on the series, varies between 0.17% and 3.8% (Ratner et al., 2000). 
The frequency is higher in more aggressive histological subtypes and in recurrent tumors. 
Due to the high risk of local recurrence, basal cell carcinomas with perineural invasion 
require specific management. The majority of authors agree on the use of Mohs surgery as 
the treatment of choice for this type of tumor; however, the use of other therapeutic options, 
such as adjuvant radiotherapy, or performing an additional Mohs stage after obtaining 
negative margins (Leibovitch et al., 2005), continues to be a subject of debate. Patients with 
gross perineural invasion manifesting neurologic symptoms would benefit from 
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preoperative magnetic resonance imaging to assess extent of tumor spread (Carucci & 
Leffell, 2008). 
9.10.3 Metastatic Basal Cell Carcinoma  
While the lifetime risk of basal cell carcinoma is high, it is well known to physicians that 
metastasis is relatively rare. Studies have indexed a metastasis rate of 0.0028% to 0.5% (Von 
Domarus & Stevens, 1984). In a review by Randle, tumors with any of the following 
characteristics should be considered high-risk for metastatic potential: long duration, 
location in the mid face or ear, diameter larger than 2 cm, aggressive histological subtype, 
previous treatment, neglected, or history of radiation (Randle, 1996). There is a 2% incidence 
of metastasis for tumors larger than 3 cm in diameter. 
Increased tissue invasion and extension of the tumor into adjacent anatomical structures 
also enhance metastatic potential (Snow et al., 1994). Immunosuppression and evidence of 
perineural spread or invasion of blood vessels have also been implicated as risk factors for 
metastasis (Robinson & Dahiya, 2003).  
For patients with metastatic disease, morbidity and mortality remain exceedingly high. The 
biggest risk factors for metastasis are tumor size, depth, and recurrence, despite optimal 
treatment. Primary basal cell carcinoma metastasizes usually via lymphatics, although it 
also spreads hematogenously. Metastasis most commonly occurs in regional lymph nodes, 
lung, and bone. 
If nodal disease is suspected on  surgical examination, lymph node biopsy and imaging 
studies, as well as  evaluation by medical and surgical oncologists, are indicated. Platinium- 
based chemotherapy has been used with modest results in treatment of metastatic BCC; 
however rapid clinical response was reported using a combination and paclitaxel (Carucci & 
Leffell, 2008). 
10. Course and prognosis 
The prognosis of basal cell cancer is very good. Patient’s survival rate is 100% without 
metastasis. However, rare in advanced cases can lead to serious morbidity and cosmetic 
problems. 
The incidence of basal cell carcinoma is increasing with each passing day, consequently 
increases in the rate of metastatic BCC (MBCC). Therefore, the prognosis is important for 
early detection and treatment of cases of BCC. 
Metastatic BCC is extremely rare. Rates reported in the literature of metastatic BCC are 
between 0.0028% and 0.5% (Berlin et al., 2002; Cotran, 1961; Malone et al., 2000). Criteria for 
the diagnosis of metastatic BCC were first described in 1951 by Lattes and Kessler. These are 
as follows: 
1. Primary tumor is originated from the skin and not from mucous membranes or other 
glands 
2. Metastasis occurred to a distant site from the primary tumor and could not result from 
direct extension 
3. Both metastatic and primary tumors have identical histopathology 
4. No squamous cell features may be present (Ozgediz et al., 2008). 
BCC metastases could be occured by lymphatic, hematogenic, or direct infiltration of 
subcutaneous tissue (Von Domarus & Stevens, 1984). 
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The most common areas of metastasis are lymph nodes, lungs, bone, skin (Berlin et al., 
2002), and parathyroid glands (Wadhera et al., 2006). 85-90% of metastatic BCC is due to 
head and neck region (Wadhera et al., 2006). More than 300 cases of metastatic BCC have 
been reported in the literature (Spates et al., 2003). 
The median age of the first sign of metastasis has been reported as 59, with the interval from 
onset of primary tumor to the time of metastasis ranging from <1 to 45 years.  
A limited number of reviews have elucidated several possible risk factors for developing 
MBCC (Table 4). 
The prognosis of metastatic BCC is usually very poor. The median survival time was 8 
months after the first metastasis, although it has been reported in patients with longer 
survival time (Boswell et al., 2006). Only those with lymph node metastasis have limited 
survival time as 3.6 years (Pfeiffer et al., 1990). 
The risk of metastasis increases with the size of primary tumor. Those with primary tumor 
size greater than 3 cm, 2% increases the risk of developing metastasis, 25% for those greater 
than 5 cm in, 50% for those greater than 10 cm in diameter (Snow et al., 1994). 
 
 Size of tumor > 2 cm  
 Head and neck locations 
 Tumor recurrence refractory to treatment 
 Previous radiation therapy  
 Multiple primary tumors  
 Increased depth of tumor  
 Invasion of perineural space and blood vessels   
 Fair skin  
 Male  
Table 4. Generally Accepted Risk Factors of Metastatic Basal Cell Carcinoma. 
Some BCC species and locations are more likely to metastasize. Today, very large size 
attained is reported cases of BCC. Giant BCC is rarely seen and constitute 1% of all cases of 
BCC. Rates of local invasion and metastasis of making Giant BCC is higher (Varga et al., 
2011). Early diagnosis and treatment can not be done in cases of localized BCC. Periorbital 
BCC may lead to blindness as a result of orbit propagation. Cases of BCC in the medial 
region of cantus deep seated and tend to be invasive. BCC cases of this type of may lead to 
perineural invasion and neural dysfunction (Bader, 2011). 
Poor prognosis could be avoided by early diagnosis and treatment, various patient’s self 
sufficient treatments and sun protection (Wong et al., 2003). Oral retinoid therapy may 
prevent or delay the development of new BCC lesions in patients with a high degree of 
actinic damaged skin, Gorlin syndrome patients and renal transplant patients (Hodak et al., 
1987). 
11. Recurrence 
5-year recurrence rate of BCC is approximately 4-5% (Kyrgidis et al., 2010). Tumour 
localization, T-stage, histologic subtype (Pieh et al., 1999) and the choice of treatment are 
significant predictors of the risk of recurrence. The relapse rate for primary basal cell 
carcinomas on the T-region of the face and nose is highest. T2 and T3 tumours show a 2- and 
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3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas. Patients 
with chronic skin diseases have a 50% lower risk of relapse than healthy patients. Recurrent 
basal cell carcinomas have a higher relapse rate than primary lesions. Patients treated in a 
specialized skin cancer unit have a 6,4-fold higher cure rate compared with those treated by 
less experienced physicians (Bogelund et al., 2007). Recurrence 5-year rate due to various 
treatments is summarized in the following table 5. 
 
 Surgical excision - 10.1% 
 Radiation therapy - 8.7% 
 Curettage and electrodesiccation - 7.7% 
 Cryotherapy - 7.5% 
 All non-Mohs modalities - 8.7% 
 Mohs micrographic surgery - 1% 
Table 5. Recurrence rate according to the treatment choices 
Reported rates of incomplete excision of basal cell carcinoma (BCC) range from 5% to 25% 
(Farhi et al., 2007; Su et al., 2007). Incomplete excision and repeated surgical excisions are 
increased recurrence rate. A positive pathologic margin has an average recurrence rate of 
21-32,2 percent (Santiago et al., 2010).   
Following BCC patients after their treatment procedure, the probability of occuring the new 
tumor in their first 3 years is 35%, and in 5 years that ratio is 50% (Mc Loone et al., 2006).  
The median time free of second primary tumour was 7 years, while the median time free of 
recurrence was 12 years (Kyrgidis et al., 2010). For that reason, following up BCC patients 
after their treatment procedure is very important (Mc Loone et al., 2006).  Recurrence of 
incompletely excised BCC was significantly higher in younger patients, in aggressive 
histological types and in localizations like postauricular and nasogenian folds (Santiago et 
al., 2010).   
A 3-mm surgical margin can be safely used for BCC to attain 95% cure rates for lesions 2 cm 
or smaller (Gulleth et al., 2010). Issued as a clean surgical magrin, recurrence develops in 
approximately 1% in cases of BCC. Average 36.6 months of development time to recurrence 
is needed after surgery (Wetzig et al., 2010).  
Located on the face of recurrent BCC and aggressive subtypes of the best treatment is Mohs 
surgery (Mosterd et al., 2009). 5-year recurrence rate after Mohs surgery for recurrent BCC is 
approximately 5.6%. This rate is 4 times more than the other treatment modalities (surgical 
excision, radiotherapy, cryotherapy, curettage and electrodesiccation) (Rowe et al., 1989). 
A recurrence of BCC should be suspected when one of the following conditions occurs: 
 Nonhealing ulceration 
 Tissue destruction 
 Scar tissue that becomes red, scaled, or crusted or enlarges with large adjacent 
telangiectasia 
 Scar tissue that slowly enlarges over time (months) 
 Development of papule/nodule within a scar  
Histologic types of BCC at higher risk for recurrence include morpheaform (sclerotic), 
micronodular, infiltrative, and superficial (multicentric). Other conditions that contribute to 
a higher recurrence rate include recurrent tumors that have been treated previously, large 
tumors (>2 cm), and deeply infiltrating tumors (Bader, 2011). 
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In immunocompromised patients, the risk of developing BCC is 10-16 times higher than the 
normal population. The risk of BCC in patients with renal transplant recipients is 
approximately 15% and female patients are at greater risk of BCC development. Recurrence 
rate after surgery is 10% (Mertz et al., 2010). However, placement and choice of treatment in 
these patients revealed no difference in terms of the normal population and does not seem 
to act more aggressively (Lott et al., 2010). 
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